n-Lorem Foundation Identifies New, Important Roles of JIP3, Offering Critical Insights into Therapeutic Approaches for Nano-rare Patients
n-Lorem, a nonprofit foundation, announced today the publication of new research characterizing a nano-rare mutation in a gene that is pivotal to normal cell signaling and cellular homeostasis. The mitogen-activated protein kinase 8 interacting protein 3 ( MAPK8IP3 ) gene encodes for c-Jun N-terminal kinase-interacting (JNK-interacting) protein 3 (JIP3). Mutations in the MAPK8IP3 gene have been linked to severe neurodevelopmental disorders, however, the mechanisms of JIP3 underlying these deleterious effects were poorly understood. In this publication, n-Lorem scientists identified several significant roles JIP3 could play in the body, characterized a mutation in MAPK8IP3 and identified a path forward to use antisense oligonucleotide (ASO) medicines to address mutations in the MAPK8IP3 gene. The study, authored by n-Lorem scientist Wei Zhang, et al was published today in JCI Insights ( JCI Insight. 2025; 10(8):e187199).
'The work described in this manuscript is exemplary of some of the challenges in defining a therapeutic strategy for nano-rare patients who have de novo mutations in genes,' said Stanley Crooke, M.D., Ph.D., Chairman, Founder and CEO of n-Lorem. 'As is often the case, the nature of the MAPK8IP3 mutation, whether loss-of-function or toxic gain-of-function, was not clearly proven before we started this. Since ASOs can be designed to carry out a variety of actions, we must know at the onset of the program if we need to alter mRNA splicing or increase or decrease protein expression. Additionally, it is often unclear what the proximal molecular events are. This information is essential to know if we are likely to correct the phenotype and potentially improve the condition.'
'At The Wolverine Foundation, our focus is to turn cutting-edge science into tangible hope for the children affected by MAPK8IP3-related neurodevelopmental disorders,' said Amy McCooe, Executive Director of The Wolverine Foundation. 'The study published in JCI Insight points to antisense oligonucleotides as a promising avenue worth pursuing. Although much remains to be learned about the therapeutic potential of this approach, we are encouraged by these findings and grateful to n-Lorem's scientists for moving us a meaningful step forward.'
The study, titled 'A toxin gain-of-function variant in MAPK8IP3 provides insights into JIP3 cellular roles,' investigated a patient with a missense mutation in the MAPK8IP3 gene (c. 1714 C > T, Arg578Cys) linked to dystonia, gross motor dysfunction and developmental delays. Aimed at uncovering the molecular mechanisms driving the cytotoxicity of MAPK8IP3 mutations the research sheds new light on the cellular functions of JIP3 and its role in neurodevelopmental disorders. The study revealed, for the first time, that the Arg578Cys mutation in JIP3 was shown to trigger cellular abnormalities that culminate in cell death and neurodegenerative disease in patients with this mutation. Funded by the Wolverine Foundation, the study also revealed that this toxic gain-of-function variant disrupts JIP3's molecular interactions, selectively impairing dopamine receptor 1 signaling while sparing dopamine receptor 2 pathways. Since disruptions in dopamine signaling are closely linked to movement disorders like Parkinson's disease, these findings may explain the motor symptoms observed in the patient.
'The significance of JIP3 has been unfolding over the last few years, but a comprehensive understanding of its functioning has been incomplete,' Crooke said. 'This research has offered us new insight into the role of JIP3 and how mutations in the protein can contribute to neurodegenerative disorders. This work could not have been completed without support from the Wolverine Foundation, and we want to thank them for their confidence and patience as we embarked on this work together.'
The Wolverine Foundation is dedicated to advancing research and discover novel therapeutic approaches to treat the neuro-developmental disease caused by genetic variations in the gene MAPK8IP3. The organization investigates disease mechanisms and encourages scientific collaboration between academic research, drug discovery and clinical development.
About n-Lorem
n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem received over 330 applications for treatment with more than 160 nano-rare patients approved and more than 25 patients on active treatment. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. Follow us on Twitter, Facebook, LinkedIn and YouTube.
To learn more about n-Lorem's mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these patients and families in need.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250508847067/en/
CONTACT: n-Lorem Contact:
Amy Williford, Ph.D.
Executive Director of Communications
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH HEALTH GENETICS PHILANTHROPY FOUNDATION OTHER HEALTH
SOURCE: n-Lorem Foundation
Copyright Business Wire 2025.
PUB: 05/08/2025 09:05 AM/DISC: 05/08/2025 09:05 AM
http://www.businesswire.com/news/home/20250508847067/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Akyso Therapeutics Expands Pipeline with New NIH Grant for Buprenorphine Implant Following Successful Phase 1a Trial of Naltrexone Implant
SALISBURY, Md.--(BUSINESS WIRE)-- Akyso Therapeutics, a privately held biotechnology company developing long-acting subcutaneous drug delivery systems, today announced two major milestones: (1) the successful completion of its first-in-human Phase 1a clinical trial of iSTEP-N®, a bioabsorbable extended-release naltrexone implant for opioid use disorder (OUD) engineered to delivery naltrexone for 12 months following a single, simple, in office treatment, and (2) the receipt of $15 million in federal funding from the National Institute on Drug Abuse (NIDA) to develop a parallel12 month buprenorphine-based implant (iSTEP-B®) for OUD. The iSTEP products represent disruptive ultra long acting formulations of both naltrexone and buprenorphine and with them Akyso Therapeutics is poised to capture a large portion of the $3B OUD treatment market in the US. Share Key Highlights: Phase 1a trial demonstrated that the iSTEP-N® implant was well-tolerated with no serious adverse events or implant-related complications. Sustained therapeutic plasma levels of naltrexone were observed for three months following a single implant. Residual Naltrexone content of the implant after 3-months suggests potential for 12-month efficacy. The iSTEP® platform utilizes a proprietary, fully bioabsorbable polymer system that does not require surgical removal. A Phase 1b study in patients with OUD is planned for early 2026 and will include a comparison to Vivitrol®. $15 million NIDA grant awarded for the development of a 6-12-month extended-release buprenorphine implant, iSTEP-B®. 'We are thrilled to share not only the success of our Phase 1a iSTEP-N® trial, but also the launch of our buprenorphine implant program with support from NIDA,' said Steven Cohen, MD, FACS, co-founder and co-CEO of Akyso Therapeutics. 'This expanded funding and validation from the NIH will allow us to pursue our dual-track approach to transforming OUD treatment with both naltrexone and buprenorphine.' Naltrexone and buprenorphine formulations represent over 90 percent of treatment options for OUD in the United States. The iSTEP products represent disruptive ultra long acting formulations of both naltrexone and buprenorphine and with them Akyso Therapeutics is poised to capture a large portion of the $3B OUD treatment market in the US. The new buprenorphine implant project builds directly upon Akyso's iSTEP® platform. iSTEP-B® will use the same bioabsorbable, subcutaneous delivery system as iSTEP-N®, with the goal of delivering therapeutic buprenorphine levels continuously for more than six months. The company plans to follow a similar clinical development pathway, including formulation, CMC analytics, GLP toxicology, and human trials. 'Our goal is to offer patients long-acting, discreet treatments that reduce relapse risk during the most vulnerable stages of recovery,' said Jeffrey Benner, MD, co-founder and co-CEO. 'With iSTEP-N® entering patient trials and iSTEP-B® now funded for development, we are well-positioned to provide scalable, very long acting, implantable therapies for both opioid and alcohol use disorders.' Akyso's iSTEP-N® program is supported in part by NIDA (UH3DA048338). A description of the Phase 1a trial is available on under the identifier NCT06053197. The new iSTEP-B® buprenorphine program is supported by a separate $15 million federal grant (2025–2029). For more information on Akyso Therapeutics or partnership opportunities, please contact:
Business Wire
an hour ago
- Business Wire
Seek Labs Maps High-Burden Mosquito-Borne Infectious Diseases with BioSeeker™, Accelerating Therapeutic Discovery for Chikungunya, West Nile Virus, and Zika
SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of three of the world's most persistent mosquito-borne infectious diseases—Chikungunya, West Nile Virus, and Zika—using its proprietary BioSeeker™ discovery engine. These newly mapped targets represent a critical expansion of the company's Global Disease Atlas and a major step forward in enabling the development of programmable therapeutics with Seek Labs' PTAP™ platform to combat vector-borne disease threats worldwide. By unlocking targets for Chikungunya, West Nile Virus, and Zika, BioSeeker has compressed years of discovery into weeks, paving the way for programmable, pathogen-specific therapeutics that could be deployed when and where they're needed most. BioSeeker Powers Precision Genomics for Programmable Therapeutics BioSeeker™ is Seek Labs' molecular strategist. By scanning thousands of viral and pathogenic genomes, it identifies conserved, high-potential sequences essential to disease survival and replication. These 'genomic weak points' serve as blueprints for Seek Labs' Programmable Target Ablation Platform (PTAP™), which utilizes CRISPR systems to irreversibly disable pathogens with genomic precision. By unlocking targets for Chikungunya, West Nile Virus, and Zika, BioSeeker has compressed years of discovery into weeks, paving the way for programmable, pathogen-specific therapeutics that could be deployed when and where they're needed most. 'Mosquito-borne diseases are among the most complex and under-addressed in global health, spanning diverse pathogens, vectors, and regions with limited therapeutic tools,' said Jared Bauer, CEO of Seek Labs. 'BioSeeker gives us a global vantage point and a tactical advantage: we know where to strike, and we have the tools to do it.' Global Burden and Urgency Mosquito-borne viral diseases infect over 400 million people each year and remain some of the most overlooked threats in global and regional public health: Chikungunya, spread by Aedes mosquitoes, causes chronic joint pain and has resurged in explosive outbreaks across Asia and the Americas. Zika, also Aedes -borne, is linked to birth defects and neurological disorders, particularly devastating in pregnant individuals. West Nile Virus is spread primarily by Culex mosquitoes and, while many cases are asymptomatic, severe neuroinvasive disease can result in encephalitis, paralysis, and death, especially among older adults and immunocompromised individuals. Despite their scale, these diseases have no approved therapeutics in routine use. As vector ranges expand due to shifting climate conditions and urbanization, the window to respond grows narrower and the need for scalable, regionally adaptable solutions is greater. Additionally, recent reports of West Nile Virus in Utah have brought this growing threat even closer to Seek Labs' doorstep, underscoring the importance of local preparedness alongside global response. A Global Call to Partner in Programmable Therapeutics for Chikungunya, West Nile Virus, and Zika With pathogen mapping complete and PTAP guide designs ready for validation, Seek Labs is actively seeking development partners to advance these targets into the next generation of programmable infectious disease therapeutics. The company invites mission-aligned collaborators—including biopharma developers, government agencies, and global health organizations—to accelerate this next phase and help redefine what's possible in mosquito-borne disease control. About Seek Labs At Seek Labs, we don't wait for change—we build it. We're pursuing the breakthroughs the world can't wait for by developing programmable 'seek-and-destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release includes forward-looking statements about Seek Labs' technologies, development plans, and partnership opportunities. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ. The technologies described are investigational and have not been reviewed or approved by the FDA or any other regulatory authority for clinical or commercial use.
Business Wire
2 hours ago
- Business Wire
New Data Show Better Outcomes for Hospitalized Surgical Patients
WASHINGTON--(BUSINESS WIRE)--Patients in the hospital for surgeries had better outcomes in 2024 than they did in 2019, according to a new report released today by the American Hospital Association and Vizient®. The significant improvement aligned not only with better performance on patient safety metrics — such as reductions in infections and falls — but also with marked declines in three major surgical patient safety indicators: severe bleeding, sepsis and respiratory failure. The new findings build on a report AHA released in collaboration with Vizient last year showing that hospitals and health systems performed better on key patient safety and quality measures in the first quarter of 2024 than they did before the COVID-19 pandemic. In fact, hospitals' efforts to improve safety led to 200,000 Americans hospitalized between April 2023 and March 2024 surviving episodes of care they wouldn't have in 2019. 'The safety and quality improvements in surgical outcomes underscore the resilience and unwavering commitment of hospitals and health systems — and the millions of hospital team members across the country — to delivering better care to the patients and communities they serve,' said AHA President and CEO Rick Pollack. 'While hospitals are proud of these efforts, we know there is always more work to do to deliver the highest quality care possible.' 'These results of this analysis reflect the extraordinary efforts by hospitals to adapt and elevate surgical care,' said David Levine MD, Senior Vice President and Chief Medical Officer for Vizient. 'By leveraging advanced analytics and technology-driven insights, health systems are not only addressing the increasing complexity of inpatient surgical cases but are improving outcomes in meaningful, measurable ways.' KEY FINDINGS FROM TODAY'S REPORT In the first quarter of 2024, hospitalized surgical patients were nearly 20% more likely to survive than expected — based on the severity of their illnesses — compared to patients in the fourth quarter of 2019. This significant improvement aligned not only with better performance on patient safety metrics — such as reductions in infections and falls — but also with declines in three high-risk post-operative complications: hemorrhage (down 22.6%), sepsis (down 9.2%) and respiratory failure (down 18.9%). As an increasing number of surgical procedures shift to outpatient or ambulatory settings, the surgical patients who remain hospitalized tend to have greater clinical complexity and require higher acuity care. Vizient projects that this trend will continue to intensify over the next decade. The average length of stay for hospitalized surgical patients has increased by nearly one full day over the past five years. This rise correlates with increasing patient acuity and the concerning trend among commercial insurers to delay discharges and deny coverage for appropriate post-acute care services. About Vizient, Inc. Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at About the American Hospital Association (AHA) The American Hospital Association (AHA) is a not-for-profit association of health care provider organizations and individuals that are committed to the health improvement of their communities. The AHA advocates on behalf of our nearly 5,000 member hospitals, health systems and other health care organizations, our clinician partners – including more than 270,000 affiliated physicians, 2 million nurses and other caregivers – and the 43,000 health care leaders who belong to our professional membership groups. Founded in 1898, the AHA provides insight and education for health care leaders and is a source of information on health care issues and trends. For more information, visit the AHA website at
